GLP-1 Medications: The Complete 2026 Guide to Every Approved Medicine and How They Compare

In the first weeks of 2026, a pharmacist in a mid-sized American city noticed something new on her counter: a small bottle instead of a cold pen. The first daily pill approved for chronic weight management, an oral form of semaglutide sold as Wegovy, had cleared US regulators in late December 2025 and was reaching patients as of February 2026. Search interest in GLP-1 medications, already enormous, spiked again.

The pill is only the latest chapter. Over the past two years these medicines picked up approvals for heart protection, kidney disease, a form of fatty liver disease and sleep apnea, and in September 2025 the World Health Organization published its first guideline on their use for obesity and added them to its Essential Medicines List.

What follows is the whole map: every approved medicine, how they differ, what the trials actually measured and where the evidence thins out. No hype, no shortcuts, and no decisions that belong anywhere other than with you and your prescribing clinician.

What is GLP-1, and why does a gut hormone matter so much?

Glucagon-like peptide-1, shortened to GLP-1, is a hormone released by specialized cells lining the small intestine within minutes of food arriving. Its job is coordination. It tells the pancreas to release insulin, but only when blood sugar is rising; it quiets glucagon, the hormone that pushes the liver to release stored sugar; it slows the rate at which the stomach empties; and it signals the brain’s appetite centers that a meal is underway.

Natural GLP-1 has one practical flaw. An enzyme called DPP-4 breaks it down in about two minutes, so the signal fades almost as soon as it starts. That brevity is exactly what pharmaceutical chemists set out to fix. By altering the molecule so DPP-4 cannot grip it, and in some cases by attaching a fatty-acid chain that binds to albumin in the blood, they stretched a two-minute signal into a drug that lasts a full day (liraglutide) or a full week (semaglutide, dulaglutide, tirzepatide).

The result is a class called GLP-1 receptor agonists. A receptor agonist is simply a molecule that fits the same cellular lock as the natural hormone and turns the same key, only for longer and at a steadier level than the body manages on its own.

The appetite effect deserves a plain explanation because it is the one most people feel. GLP-1 receptors sit in the hypothalamus and brainstem, regions that weigh hunger against fullness. When those receptors stay activated, meals feel satisfying sooner, between-meal cravings soften and many people describe a quieter relationship with food. That is a physiological change, not a test of willpower, and understanding it is the first step toward understanding why GLP-1 medications behave so differently from older appetite drugs.

What changed recently with GLP-1 medications

The pace of approvals since 2024 is the main reason this class keeps trending. The dates below are drawn from the regulatory labels summarized by MedlinePlus and the clinical summaries at Mayo Clinic and Cleveland Clinic listed in the references.

• March 2024: Wegovy (injectable semaglutide) gained a US indication to reduce the risk of heart attack, stroke and cardiovascular death in adults with established heart disease and overweight or obesity, based on the SELECT trial.
• Mid 2024 and 2025: Generic liraglutide became available in the United States, first for the diabetes product (Victoza) and later for the weight-management product (Saxenda), the first GLP-1 generics in the country.
• December 2024: Zepbound (tirzepatide) was approved for moderate to severe obstructive sleep apnea in adults with obesity.
• January 2025: Ozempic (semaglutide) was approved to slow kidney disease progression in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial.
• May 2025: The first large head-to-head trial, SURMOUNT-5, reported that tirzepatide produced more weight loss than semaglutide over 72 weeks.
• August 2025: Wegovy received accelerated approval for metabolic dysfunction-associated steatohepatitis, or MASH, a fatty liver disease with inflammation, in adults with moderate to advanced scarring.
• September 2025: WHO issued its first guideline on GLP-1 therapies for obesity and added semaglutide, tirzepatide, liraglutide and dulaglutide to its Essential Medicines List.
• December 2025: US approval of oral semaglutide (the Wegovy pill) for chronic weight management, the first GLP-1 tablet for that purpose.

Two things did not change. No GLP-1 medication is approved for cosmetic or short-term weight loss in people without a qualifying diagnosis, and none is approved for prediabetes. Those boundaries matter when we get to the myths.

How does Ozempic work? The mechanism behind every GLP-1 medicine

Ozempic is the brand of injectable semaglutide approved for type 2 diabetes, and because it is the name most people type, it makes a useful stand-in for the whole class. Semaglutide is a modified copy of human GLP-1. Two amino acids were swapped to resist DPP-4, and a fatty-acid side chain was added so the molecule rides on albumin in the bloodstream. Those tweaks give it a half-life of about a week, which is why one injection covers seven days.

Once in circulation, semaglutide acts on four fronts at once:

• Pancreas: it increases insulin release only when glucose is high, which is why GLP-1 medicines alone rarely cause dangerously low blood sugar.
• Liver: it suppresses glucagon, reducing the liver’s tendency to pour out sugar between meals.
• Stomach: it slows gastric emptying, flattening the sugar spike after eating and extending the feeling of fullness.
• Brain: it activates appetite-regulating receptors in the hypothalamus and brainstem, lowering hunger and the pull of high-calorie foods.

Harvard Health and Cleveland Clinic both point out that the stomach-slowing effect fades somewhat over months while the brain effect persists, which fits what patients report: early nausea often improves, while reduced appetite continues.

Every approved GLP-1 medicine shares this core mechanism. The differences lie in how long each lasts, whether it also activates a second hormone receptor (tirzepatide does), and whether it is injected or swallowed. Oral semaglutide (Rybelsus for diabetes, the Wegovy pill for weight) needs an absorption enhancer to survive stomach acid, and the pharmacist’s instructions on food timing exist for that reason. Mechanistically the molecule is the same; the delivery route is what changes.

Every approved GLP-1 medication in 2026: the full list

Five active ingredients make up the entire approved GLP-1 class in the United States, sold under about ten brand names. Here is the complete roster, grouped by molecule.

• Semaglutide: Ozempic (weekly injection; type 2 diabetes, cardiovascular risk, chronic kidney disease), Wegovy injection (weekly; chronic weight management, cardiovascular risk, MASH), Wegovy tablets (daily; chronic weight management) and Rybelsus (daily tablet; type 2 diabetes).
• Tirzepatide: Mounjaro (weekly injection; type 2 diabetes) and Zepbound (weekly; chronic weight management and obstructive sleep apnea). Tirzepatide activates both GLP-1 and GIP receptors, so it is technically a dual agonist rather than a pure GLP-1 drug.
• Liraglutide: Victoza (daily injection; type 2 diabetes in adults and children aged 10 and older) and Saxenda (daily; chronic weight management in adults and adolescents 12 and older). Generic liraglutide is now available for both uses. Saxenda’s generic name is simply liraglutide.
• Dulaglutide: Trulicity (weekly injection; type 2 diabetes in adults and children 10 and older, with a cardiovascular risk-reduction indication).
• Exenatide: Byetta (twice-daily injection) and the extended-release Bydureon BCise (weekly), both for type 2 diabetes. These are the oldest members of the class, approved in 2005 and 2012, and are prescribed far less often today.

Two fixed-dose combinations pair a GLP-1 medicine with a long-acting insulin for type 2 diabetes: Xultophy (insulin degludec with liraglutide) and Soliqua (insulin glargine with lixisenatide). Lixisenatide on its own (Adlyxin) was withdrawn from the US market in 2023 for commercial reasons, not safety.

For weight management specifically, the approved options are Wegovy (injection or tablet), Zepbound and Saxenda. Ozempic, Mounjaro, Rybelsus, Trulicity and the exenatide products are diabetes medicines; any use for weight alone is off-label, and that decision belongs to the treating clinician.

Semaglutide explained: Ozempic, Wegovy, Rybelsus and the new Wegovy pill

Semaglutide is the most studied molecule in the class and the only one available in four different products. Understanding how they differ clears up a great deal of confusion.

Ozempic was approved for type 2 diabetes in 2017. Its label grew to include reducing major cardiovascular events in people with diabetes and heart disease (2020) and slowing kidney decline in diabetic chronic kidney disease (2025). Weight loss is a well-documented effect but not an approved indication.

Wegovy injection is the same molecule at higher strengths, approved in 2021 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, and in 2022 for adolescents aged 12 and older with obesity. The 2024 cardiovascular indication was a landmark: SELECT enrolled more than 17,000 adults without diabetes and found a 20 percent relative reduction in heart attack, stroke or cardiovascular death over about three years. In absolute terms, events occurred in 6.5 percent of the semaglutide group versus 8 percent on placebo. The 2025 MASH indication rests on a trial showing resolution of liver inflammation in roughly twice as many treated participants as placebo.

Rybelsus (2019) is the oral diabetes form. Because peptides are destroyed by stomach acid, it is paired with an absorption enhancer and carries specific instructions about food and other medicines.

Wegovy tablets, approved December 2025, bring the oral technology to weight management. In the OASIS 4 trial, participants lost an average of about 14 percent of body weight over 64 weeks versus about 2 percent on placebo, a result close to the injectable in its own trials, though the two were never compared directly.

MedlinePlus lists all four under the single entry for semaglutide, a reminder that the active ingredient is identical even when the packaging, strength and indication are not.

Tirzepatide: why Mounjaro and Zepbound are not strictly GLP-1 drugs

Tirzepatide earns a separate section because it works through two hormones rather than one. Alongside GLP-1 it activates the receptor for glucose-dependent insulinotropic polypeptide, or GIP, a second gut hormone released from the upper small intestine that also boosts insulin and appears to influence how fat tissue handles energy. Pharmacologists call it a dual GIP/GLP-1 receptor agonist. In everyday conversation it is lumped in with GLP-1 medications, and that is reasonable, but the second mechanism likely explains its larger effect on weight.

Mounjaro was approved for type 2 diabetes in 2022. In the SURPASS trials it lowered hemoglobin A1c, the three-month average blood sugar marker, by more than any previously tested injectable, with weight loss as a prominent secondary effect.

Zepbound followed in November 2023 for chronic weight management. In SURMOUNT-1, a 72-week randomized trial of adults with obesity and without diabetes, average weight loss ranged from about 15 percent in the lowest-strength arm to about 21 percent in the highest, against roughly 3 percent on placebo. A three-year extension reported in 2024 found that participants with prediabetes at baseline were about 94 percent less likely to progress to type 2 diabetes while on treatment.

The sleep apnea indication came in December 2024. In adults with obesity and moderate to severe obstructive sleep apnea, tirzepatide reduced the apnea-hypopnea index, the number of breathing interruptions per hour of sleep, by roughly 25 to 29 events compared with about 5 on placebo. Weight loss drove much of this, since fat around the neck and tongue narrows the airway.

Then came SURMOUNT-5, the comparison everyone wanted. Over 72 weeks, adults on tirzepatide lost about 20 percent of body weight versus about 14 percent on semaglutide. Both groups had similar rates of gastrointestinal side effects. It is one trial, open-label rather than blinded, but it is the best direct evidence we have.

How do GLP-1 medications compare? Side-by-side summary

The table pulls together what the pivotal trials measured. Weight figures are average placebo-subtracted or total losses from the main randomized trial for each product in adults without diabetes where available; people with diabetes typically lose somewhat less. Because the trials differed in length and populations, treat the numbers as a guide to scale, not a ranking to the decimal point.

Generic (brands)	Receptor target	How taken	Approved uses	Average weight loss in key trial
Semaglutide (Wegovy injection)	GLP-1	Weekly injection	Weight management, cardiovascular risk, MASH	About 15% at 68 weeks (STEP 1)
Semaglutide (Wegovy tablets)	GLP-1	Daily tablet	Weight management	About 14% at 64 weeks (OASIS 4)
Semaglutide (Ozempic, Rybelsus)	GLP-1	Weekly injection or daily tablet	Type 2 diabetes; Ozempic also heart and kidney protection	About 4–7% in diabetes trials
Tirzepatide (Zepbound)	GLP-1 and GIP	Weekly injection	Weight management, obstructive sleep apnea	About 15–21% at 72 weeks (SURMOUNT-1)
Tirzepatide (Mounjaro)	GLP-1 and GIP	Weekly injection	Type 2 diabetes	About 7–13% in diabetes trials
Liraglutide (Saxenda, generic)	GLP-1	Daily injection	Weight management, adults and adolescents 12+	About 8% at 56 weeks (SCALE)
Liraglutide (Victoza, generic)	GLP-1	Daily injection	Type 2 diabetes, cardiovascular risk	About 2–3%
Dulaglutide (Trulicity)	GLP-1	Weekly injection	Type 2 diabetes, cardiovascular risk	About 2–5%
Exenatide (Byetta, Bydureon BCise)	GLP-1	Twice daily or weekly injection	Type 2 diabetes	About 2–3%

Three patterns stand out. Longer-acting molecules outperform shorter ones. The dual-agonist tirzepatide outperforms single-agonist semaglutide in the one direct trial. And the oral and injectable forms of semaglutide land in a similar range, which means the choice between them turns on tolerance, convenience and clinical judgment rather than raw efficacy. Which medicine, if any, suits a given person is a decision for the prescribing clinician, who also weighs kidney function, other medicines, pregnancy plans and personal and family history.

What the evidence actually says, graded by strength

Not every claim about GLP-1 medications rests on the same foundation. Here is an honest grading, using three tiers: randomized controlled trials (participants assigned by chance to drug or placebo, the strongest design), observational data (large real-world records that can show associations but not prove cause) and expert opinion.

Strong, from randomized trials:

• Blood sugar lowering in type 2 diabetes: dozens of trials across all five molecules.
• Weight loss of roughly 6 to 21 percent depending on the agent: STEP, SURMOUNT, SCALE and OASIS programs, each enrolling thousands.
• Cardiovascular protection: SELECT (semaglutide without diabetes), SUSTAIN-6 and LEADER (semaglutide and liraglutide with diabetes), REWIND (dulaglutide).
• Kidney protection in diabetic kidney disease: FLOW showed a 24 percent relative reduction in kidney failure, major loss of function or kidney or cardiovascular death.
• Improvement in sleep apnea severity with tirzepatide: two randomized trials.
• Weight regain after stopping: a randomized extension of STEP 1 found participants regained about two-thirds of lost weight within a year of withdrawal.

Moderate, mostly observational or short-term:

• Reduced alcohol consumption and other reward-seeking behaviors: consistent signals in health-record studies and small trials, but no definitive large trial.
• Lower rates of several obesity-related cancers in treated populations: observational only, confounded by weight loss itself.
• Proportion of weight lost as muscle versus fat: body-composition substudies suggest roughly a quarter to two-fifths of lost weight is lean mass, similar to diet-induced loss, but long-term functional consequences are unmeasured.

Expert opinion or unresolved:

• Whether treatment should be lifelong or can be tapered: guidelines describe obesity as chronic and relapsing, but no trial has tested a structured off-ramp.
• Effects on fertility, pregnancy and breastfeeding: animal data and small human series only; the labels advise stopping before a planned pregnancy.

Harvard Health frames the balance well: the core benefits are among the best-documented in modern pharmacology, while the questions that dominate social media sit mostly in the lower two tiers.

Beyond weight: heart, kidney, liver and sleep apnea benefits

The most consequential shift in how clinicians think about GLP-1 medications is that weight is no longer the only endpoint that counts. Four organ systems now have randomized evidence behind them.

Heart. SELECT enrolled adults with prior heart attack, stroke or peripheral artery disease who had overweight or obesity but not diabetes. Semaglutide reduced the composite of heart attack, stroke and cardiovascular death by 20 percent relative to placebo over a median of about 40 months. Intriguingly, the benefit appeared within months, before most weight loss had occurred, hinting at effects on inflammation and blood vessel function beyond weight. The American Heart Association now recognizes GLP-1 therapy as a tool for cardiovascular risk reduction in this group.

Kidney. FLOW tested semaglutide in more than 3,500 adults with type 2 diabetes and chronic kidney disease. The trial stopped early for efficacy: a 24 percent lower risk of major kidney events and a slower decline in filtration rate. Earlier trials of liraglutide and dulaglutide had shown reduced protein leakage in urine, a marker of kidney stress.

Liver. MASH affects an estimated 1 in 20 US adults and can progress to cirrhosis. In the ESSENCE trial, semaglutide resolved liver inflammation without worsening scarring in about 63 percent of participants versus 34 percent on placebo, and improved fibrosis in about 37 percent versus 22 percent. The approval is accelerated, meaning longer-term outcome data are still being collected.

Sleep apnea. In the SURMOUNT-OSA trials, tirzepatide cut breathing interruptions by more than half in many participants and roughly 40 to 50 percent reached a point where their apnea was mild or resolved on testing. Participants using a CPAP machine and those not using one both benefited.

Each of these indications applies to a defined population. A person with none of these conditions does not inherit these benefits by assumption, and whether any of them apply to you is a conversation for your clinician.

Can GLP-1 medication help with prediabetes?

Prediabetes means blood sugar is above normal but below the diabetes threshold: a hemoglobin A1c of 5.7 to 6.4 percent, or a fasting glucose of 100 to 125 milligrams per deciliter. CDC estimates roughly 98 million US adults have it, and most do not know. Without changes, about 5 to 10 percent progress to type 2 diabetes each year.

The evidence that GLP-1 medications slow that progression is strong but indirect. In the three-year SURMOUNT-1 extension, adults with obesity and prediabetes who took tirzepatide were about 94 percent less likely to develop type 2 diabetes than those on placebo, and most saw blood sugar return to the normal range. In STEP 10, a trial of semaglutide in adults with obesity and prediabetes, about 81 percent reverted to normal glucose at 52 weeks compared with about 14 percent on placebo. Liraglutide showed similar, smaller effects in a three-year SCALE extension a decade earlier.

Here is the honest caveat. No GLP-1 medication is approved for prediabetes as a diagnosis on its own. Those trial participants qualified because they had obesity; prediabetes was a secondary feature. Prescribing for prediabetes without a weight-based indication is off-label, and the decision rests with the treating clinician, who weighs it against proven alternatives.

Those alternatives remain the foundation. The Diabetes Prevention Program, a randomized trial from 2002, found that losing about 7 percent of body weight through diet and physical activity reduced progression to diabetes by 58 percent, more than the medicine metformin achieved in the same study. CDC’s National Diabetes Prevention Program makes that structured curriculum widely available. For many people with prediabetes, that path and a GLP-1 medicine are not rivals; clinicians increasingly combine them when weight criteria are met.

GLP-1 side effects: what is common, what is rare, what is still being studied

The side-effect profile of GLP-1 medications is well mapped because so many people have been in trials. The pattern is consistent across the class.

Common and usually temporary. Gastrointestinal symptoms lead by a wide margin. In STEP 1, nausea affected about 44 percent of semaglutide users versus 16 percent on placebo; diarrhea, vomiting and constipation followed. Most episodes were mild to moderate, clustered around strength increases and eased within weeks. About 7 percent of participants stopped because of side effects, compared with about 3 percent on placebo. Fatigue, headache, burping and reduced alcohol tolerance are also reported.

Uncommon but important. Gallbladder problems, including gallstones, occurred in roughly 2 to 3 percent of trial participants, partly a consequence of rapid weight loss itself. Pancreatitis, inflammation of the pancreas, is rare but appears on every label. Low blood sugar is unusual with a GLP-1 medicine alone but becomes a real risk when combined with insulin or sulfonylurea drugs. Slowed stomach emptying occasionally progresses to gastroparesis, and anesthesiologists now ask about these medicines before surgery because of aspiration risk.

Under active study. Rodent studies showed thyroid C-cell tumors, which is why the labels carry a boxed warning and why people with a personal or family history of medullary thyroid cancer or MEN2 syndrome are advised against use; a comparable effect in humans has not been demonstrated after more than a decade of monitoring. Reports of suicidal thoughts prompted a US regulatory review in January 2024 that found no causal link, while monitoring continues. A rare eye condition, non-arteritic anterior ischemic optic neuropathy, was judged by European regulators in 2025 to be a very rare side effect of semaglutide, affecting an estimated fewer than 1 in 10,000 users.

The widely discussed facial volume loss nicknamed after Ozempic is not a drug effect; it is what losing a large amount of fat quickly looks like in the face, as Harvard Health explains.

Common myths about GLP-1 medications, checked against the evidence

Viral claims travel faster than trial results. These are the ones worth correcting.

Myth: they are just appetite suppressants, so results are no different from dieting. The mechanism involves insulin, glucagon, stomach emptying and brain signaling simultaneously, and the magnitude of weight loss in randomized trials is two to five times what intensive lifestyle programs achieve on average. Cardiovascular and kidney benefits appeared partly independent of weight.

Myth: most of the weight lost is muscle. Body-composition substudies show about 25 to 40 percent of lost weight is lean mass, in line with any substantial weight loss, including after bariatric surgery. Adequate protein and resistance training help preserve muscle, which is why clinicians pair these medicines with both.

Myth: they cause thyroid cancer in people. The warning stems from rodents, whose thyroid C-cells respond to GLP-1 in ways human cells largely do not. Human registry data over more than ten years have not confirmed an increase, though the precaution for people with specific inherited risks remains.

Myth: they cause depression and suicidal thoughts. A 2024 US regulatory review and a large European assessment found no causal relationship. Trials of semaglutide in people with obesity showed no difference in depression scores versus placebo.

Myth: the weight comes straight back, so there is no point. Regain after stopping is real and well documented, but it reflects the chronic nature of obesity, much as blood pressure rises when an antihypertensive stops. That argues for long-term planning with a clinician, not against treatment.

Myth: compounded or online versions are the same product. They are not reviewed for safety, strength or purity by regulators, and some contain different salt forms of the molecule that were never tested in humans. More on this in the next section.

Myth: they melt fat without any effort. Every pivotal trial included dietary counseling and an activity goal. The medicine made those changes achievable for people in whom biology had made them nearly impossible.

Investigational pills, compounded products and what 'not approved' really means

The pipeline behind the approved list is deep, and the names leak into headlines long before the evidence is complete.

Investigational medicines. Orforglipron is a small-molecule GLP-1 pill that does not require the absorption technology peptides need; phase 3 trials reported substantial weight loss and blood sugar lowering, and it was under regulatory review as of February 2026. CagriSema combines semaglutide with cagrilintide, a long-acting version of the hormone amylin, and produced around 20 percent weight loss in a phase 3 trial. Retatrutide targets three receptors (GLP-1, GIP and glucagon) and showed about 24 percent loss in phase 2. Survodutide and MariTide are further behind. None of these is approved for sale or use outside clinical trials. Products marketed online under these names as research peptides are unregulated, often of unknown content, and are not for sale or self-use.

Compounded semaglutide and tirzepatide. During the 2022 to 2024 shortages, US law allowed pharmacies to compound copies. The shortages were declared resolved in late 2024 and early 2025, and that allowance ended, with limited exceptions for genuine individual medical need. Compounded products are not evaluated by regulators for safety, effectiveness or manufacturing quality, and poison-control centers logged a sharp rise in overdose calls linked to measurement errors with vials. Some products used semaglutide sodium or acetate salts that differ from the approved molecule and have no human data.

What approval signals. An approved GLP-1 medication has been tested in randomized trials with thousands of participants, is manufactured under inspected conditions, carries a label listing exactly who should and should not take it, and is monitored for new safety signals after launch. That chain is the reason this article can quote percentages with confidence. It is also why anyone considering these medicines should obtain them only through a prescribing clinician and a licensed pharmacy.

When to see a doctor about GLP-1 medications

Every decision about starting, continuing, adjusting or stopping a GLP-1 medication belongs with your prescribing clinician. These are the moments when that conversation should happen promptly.

Before starting, see a doctor if you:

• Have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
• Have had pancreatitis, gallbladder disease or diabetic eye disease (retinopathy), which can temporarily worsen with rapid glucose improvement.
• Take insulin or a sulfonylurea, since low blood sugar risk rises when they are combined.
• Are pregnant, planning pregnancy within the coming months or breastfeeding.
• Have a history of an eating disorder or severe depression.

Seek urgent care (same day or emergency) for red flags:

• Severe, persistent abdominal pain that may spread to the back, with or without vomiting: possible pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools: possible gallbladder blockage.
• Vomiting that prevents keeping fluids down for more than a day, dizziness on standing or very dark urine: dehydration, which can injure the kidneys.
• Sudden vision loss or a dark patch in one eye.
• Shakiness, confusion, sweating or a racing heart that improves with sugar: low blood sugar.
• Swelling of the face or throat, hives or difficulty breathing: allergic reaction.
• New or worsening thoughts of self-harm.
• A lump in the neck, hoarseness that does not resolve or trouble swallowing.

Book a routine appointment if: nausea or constipation has not eased after several weeks; you are losing weight faster than you and your clinician planned; you notice hair shedding, which usually reflects rapid weight loss and settles; you have surgery or a procedure under sedation scheduled, so the team can advise on timing; or you are considering a break from treatment. Never stop or change the medicine on your own; both the benefits and the safety monitoring depend on a plan you build together.

Frequently asked questions

What are glucagon-like peptide-1 receptor agonists?

They are medicines that imitate GLP-1, a gut hormone released after eating, by fitting the same cellular receptor and activating it for a day or a week instead of two minutes. The effect is more insulin when sugar is high, less glucagon, slower stomach emptying and reduced appetite. Approved examples include semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide.

How does Ozempic work for weight loss and blood sugar?

Ozempic (semaglutide) acts on the pancreas, liver, stomach and brain at once: it raises insulin only when glucose is elevated, suppresses glucagon, slows digestion and quiets appetite centers in the hypothalamus. Blood sugar and weight both fall as a result. It is approved for type 2 diabetes, heart protection and kidney protection; using it for weight alone is off-label and a decision for the prescribing clinician.

What is the generic name for Saxenda?

Saxenda’s generic name is liraglutide, a daily GLP-1 injection approved for chronic weight management in adults and adolescents aged 12 and older. The same molecule is sold as Victoza for type 2 diabetes. Generic liraglutide became available in the United States for both uses in 2024 and 2025, making it the first GLP-1 medication with a generic version.

What is GLP-1 and where does it come from in the body?

GLP-1 stands for glucagon-like peptide-1, a hormone produced by cells in the lining of the small intestine within minutes of food arriving. It coordinates the body’s response to a meal by boosting insulin, suppressing glucagon, slowing the stomach and signaling fullness to the brain. The natural hormone is broken down in about two minutes, which is why drug versions were engineered to last far longer.

Can GLP-1 medication help with prediabetes?

Randomized trial subgroups suggest it can: tirzepatide reduced progression to type 2 diabetes by about 94 percent over three years in adults with obesity and prediabetes, and semaglutide returned glucose to normal in about 81 percent at one year. No GLP-1 medicine is approved for prediabetes alone, so any such use is off-label and belongs to the treating clinician alongside proven lifestyle programs.

Which GLP-1 medication is most effective for weight loss?

In the only large direct comparison, tirzepatide (Zepbound) produced about 20 percent weight loss over 72 weeks versus about 14 percent for semaglutide (Wegovy). Liraglutide (Saxenda) averages about 8 percent, and the diabetes-focused agents less. Effectiveness is only one factor; tolerance, other conditions and medical history shape which option, if any, a clinician recommends.

Is the Wegovy pill as effective as the injection?

The two have not been compared head to head. In its own trial, the Wegovy tablet produced about 14 percent average weight loss over 64 weeks, while the injection produced about 15 percent over 68 weeks in a separate trial with a different population. Those figures sit close enough that the choice usually comes down to tolerance, preference and clinical judgment rather than efficacy.

What are the most common GLP-1 side effects?

Gastrointestinal symptoms dominate: nausea affected about 44 percent of semaglutide users in its main trial versus 16 percent on placebo, followed by diarrhea, vomiting and constipation. Most are mild, cluster around strength increases and ease within weeks. Rarer concerns include gallbladder disease, pancreatitis and low blood sugar when combined with insulin. Severe abdominal pain or persistent vomiting warrants same-day medical attention.

Do you regain weight after stopping GLP-1 medications?

Most people regain a substantial portion. In a randomized extension of the STEP 1 trial, participants who stopped semaglutide regained about two-thirds of their lost weight within a year, and cardiometabolic markers drifted back toward baseline. Guidelines describe obesity as a chronic, relapsing condition, so any plan to pause or stop should be made with the prescribing clinician.

Are compounded or online GLP-1 medications safe?

Compounded versions are not reviewed by regulators for safety, strength or purity, and the shortage allowance that permitted them in the US ended in 2025 with narrow exceptions. Some contained untested salt forms of the molecule, and poison-control centers reported rising dosing-error calls. Investigational pills sold online as research peptides are unapproved and not for sale or self-use. Approved medicines come only through a prescriber and licensed pharmacy.

References

• Semaglutide Injection, MedlinePlus Drug Information (NIH)
• GLP-1 Agonists, Cleveland Clinic
• Obesity: Treatment, NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.